Study Objectives: Primary * To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5 or 6 on the World Health Organization (WHO) 9-point severity scale * To evaluate the safety and tolerability of three IV doses of rhu-pGSN administered to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5, or 6 on the WHO 9-point severity scale Secondary * To further assess the efficacy of IV administered rhu-pGSN * To assess changes in WHO 9-point severity score for SOC with or without rhu-pGSN * To evaluate the effect of administered rhu-pGSN on survival rates * To assess the relationship of pGSN levels (and other biomarkers) at baseline with clinical outcomes * \[OPTIONAL\] To follow the pharmacokinetics (PK) of administered rhu-pGSN Immunogenicity • To investigate the development of antibodies against rhu-pGSN post-treatment
Efficacy and safety of IV rhu-pGSN on top of SOC will be evaluated initially in 60 participants representative of the drug target population: high-risk subjects with acute severe pneumonia due to COVID-19. The rhu-pGSN dose will be based on actual body weight given at 12 mg/kg. Three doses will be given at 0, 12 and 24 hours intervals promptly after enrollment by IV infusion through a 0.2 µm filter. Participants will be randomized 1:1 rhu-pGSN or placebo. Interim safety analyses will be conducted after enrollment of 12, 24, 36, and 48 patients. The primary efficacy outcome will be the proportion of patients surviving on Day 14 without mechanical ventilation, vasopressors or dialysis. Secondary efficacy outcomes will include: daily change in 9-point WHO severity score through at least Day 14; all-cause mortality at Days 28 and 90; time to death (Kaplan-Meier survival analysis); proportion of subjects alive on Days 7, 28, 60, and 90 without: ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for dialysis/renal replacement therapy; proportion of subjects discharged to home or immediate prior residence by Day 28; days on the ventilator; length of stay in hospital and in ICU and re-admission to an acute-care hospital up to Day 90. Safety of administration of rhu-pGSN at the indicated dosage will also be evaluated. Baseline and sequential levels of pGSN and inflammatory biomarkers will be measured. On days 1, 28, and 90, immunogenicity due to the formation of anti-pGSN antibodies will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
64
Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie
Timișoara, Romania
Sant Joan de Reus SAM University Hospital
Reus, Spain
Hospital Universitari de Tarragona Joan XXIII
Tarragona, Spain
Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis
Number and percentage of subjects alive on Day 14 without ongoing use of vasopressors, ongoing intubation/mechanical ventilation, or new/ongoing need for dialysis/RRT. Subjects who discontinued from the study early or whose survival status was inconclusive on Day 14 were considered as a failure (Not Alive).
Time frame: Day 14
Safety: Number of Subjects With SAEs
Number of subjects with SAEs during the study
Time frame: Day 1 through Day 90
Efficacy: All Cause Mortality Rate at Day 90
All cause mortality rate using Kaplan-Meier survival analysis
Time frame: Day 90
Safety and Tolerability: Proportion of Subjects With Adverse Events (AEs)
Proportion of subjects with adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Continuous through Day 28
Immunogenicity: Subjects With Rhu-pGSN Antibodies
Number of subjects with rhu-pGSN antibodies at Day 28
Time frame: Day 28
Efficacy: Alive Without Support at Day 90
Number of subjects Alive without organ support at Day 90
Time frame: Day 90
Safety and Tolerability: Proportion of Subjects With Drug-related Adverse Events (AEs)
Proportion of subjects with drug-related adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Continuous through Day 14
Number of Subjects Alive Without Organ Support at Day 90
number of subjects alive and without organ support at the Day 90 visit
Time frame: Through Day 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.